For instance, Qasim et al. [43] successfully bridged 2 infants with R/R ALL to alloHCT by treating with a single dose of universal CD19+ CAR T-cells developed by lentiviral transduction and concurrent TALEN-mediated gene editing of TCR [deletion of T-cell receptor alpha constant (TRAC)]. This evidence concerns the gene TRAC and acute lymphoblastic leukemia.